Continuous glucose monitoring (CGM) system-maker Senseonics has cut a deal with Ascensia Diabetes Care and its parent company, PHC Holdings, outlining commercialization and distribution of the Eversense product line over the next few years.
According to the companies, Ascensia now holds exclusive global distribution rights for the Eversense, Eversense XL and future CGMs. The duration of the...
The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and distributors in the US that the sensors of certain devices may stop working prematurely.
Senseonics identified a small number of Eversense Sensors that have prematurely stopped functioning due to inadequate...
On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t cover the full cost of the CGM.
The new program, called Eversense Bridge, charges patients $99 for the Eversense CGM system, in addition to the cost of the sensor placement by their provider....
